Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer’s drug

Hits: 5

Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer’s drug, Aduhelm. Read More Go To Source